Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease
Clinical Parkinsonism & Related Disorders · 2025 · 13 · 100378
DOI: 10.1016/j.prdoa.2025.100378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2025. Verfasst von Makito Hirano und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kindai University, Faculty of Medicine, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dysphagia is a potentially fatal symptom of Parkinson's disease (PD) and is characterized by frequent silent aspiration, a known risk factor for aspiration pneumonia. A previous study has reported that the dopamine agonist rotigotine (levodopa equivalent dose of 60 mg/day) delivered via transdermal patch improves swallowing function more effectively than oral levodopa (200 mg/day), highlighting the importance of continuous dopaminergic stimulation (CDS) in managing dysphagia. To achieve CDS, patients with advanced PD may require device-assisted therapies (DATs), including levodopa-carbidopa intestinal gel (LCIG), which have significantly improved swallowing function on some measures. In contrast, swallowing function is an important prognostic factor for patients with PD undergoing LCIG. Continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSCI-FF) is a newly developed DAT; however, its effect on swallowing function remains unknown.
Methods
This retrospective open-label evaluator-blinded study included seven patients with PD. Swallowing function was assessed using videofluoroscopic swallow studies (VFSS) conducted before and after initiating CSCI-FF. Evaluations included the Japanese Swallowing Scale, the Dysphagia Outcome and Severity Scale (DOSS), Penetration/Aspiration Scale, oral transit time (OTT), and pharyngeal transit time (PTT).
Results
Following the introduction of CSCI-FF, results of VFSS showed significant improvement in the total score of the Japanese swallowing scale, OTT, and PTT.
Conclusions
This study provides preliminary evidence that CSCI-FF may partially improve swallowing function in patients with advanced PD. Further research with larger cohorts is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Kindai University, Faculty of Medicine, Japan.
- Division of Rehabilitation Medicine, Kindai University Hospital, Japan.
- Department of Rehabilitation Medicine, Kindai University, Faculty of Medicine, Japan.
Zitieren
APA
Hirano, M., Samukawa, M., Isono, C., Inada, R., Fukumoto, Y., Yoshikawa, K., Namura, H., Sakata, H., Hisatomi, T., Michiura, T., Nakamura, H., Morita, A., Hoshino, G., Yamana, K., Terayama, A., Higashimoto, Y., Mitsui, Y., & Nagai, Y. (2025). Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders, 13, 100378. https://doi.org/10.1016/j.prdoa.2025.100378
Vancouver
Hirano M, Samukawa M, Isono C, Inada R, Fukumoto Y, Yoshikawa K, et al. Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 2025;13:100378. doi:10.1016/j.prdoa.2025.100378
BibTeX
@article{Hirano2025,
author = {Hirano, Makito and Samukawa, Makoto and Isono, Chiharu and Inada, Rino and Fukumoto, Yuta and Yoshikawa, Keisuke and Namura, Hitoshi and Sakata, Hanami and Hisatomi, Takahiro and Michiura, Toru and Nakamura, Hiroto and Morita, Akira and Hoshino, Genki and Yamana, Kensuke and Terayama, Atsushi and Higashimoto, Yuji and Mitsui, Yoshiyuki and Nagai, Yoshitaka},
title = {Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2025},
volume = {13},
pages = {100378},
doi = {10.1016/j.prdoa.2025.100378}
}
EUVIMED